Human Acellular Vessel (HAV)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Failure

Conditions

Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access

Trial Timeline

May 24, 2016 โ†’ Sep 1, 2023

About Human Acellular Vessel (HAV)

Human Acellular Vessel (HAV) is a phase 3 stage product being developed by Humacyte for Renal Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT02644941. Target conditions include Renal Failure, End Stage Renal Disease, Hemodialysis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT03005418Phase 2/3Active
NCT03183245Phase 3Completed
NCT02887859Phase 2Completed
NCT02644941Phase 3Completed

Competing Products

20 competing products in Renal Failure

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23